Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib, are effective therapies against mutant non-small cell lung cancers (NSCLCs). Treatment is limited by the development of resistance in part explained by the gain of a secondary EGFR mutation, T790M, at the ga...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Ercan, Dalia, Zejnullahu, Kreshnik, Yonesaka, Kimio, Xiao, Yun, Capelletti, Marzia, Rogers, Andrew, Lifshits, Eugene, Brown, Alison, Lee, Charles, Christensen, James G., Kwiatkowski, David J., Engelman, Jeffrey A., Jänne, Pasi A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2010
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2859699/
https://ncbi.nlm.nih.gov/pubmed/20118985
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2009.526
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk